Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-025 in Relapsed/Refractory NKG2DL+ Solid Tumors
NCT04270461Phase 1Withdrawn
- Sponsor
- Jiujiang University Affiliated Hospital
- Start
- Mar 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belumosudil in hepatocellular carcinoma (HCC), glioblastoma (GBM), medulloblastoma and 1 more, sponsored by Jiujiang University Affiliated Hospital. Primary endpoints: Number of Participants with severe cytokine release syndrome and Copies numbers of CAR. Planned start Mar 2020; status: withdrawn.
02
Drugs
belumosudil
03
Conditions
hepatocellular carcinoma (HCC)glioblastoma (GBM)medulloblastomacolon cancer
Beyond the preview
Go deeper on NCT04270461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270461.